The three largest Western nicotine companies are executing divergent strategies as the industry enters its most competitive phase since the 2018 JUUL boom.

BAT H1 2026: U.S. Vapor Recovery Drives the Beat

British American Tobacco reported H1 2026 revenue of GBP 12.24 billion on July 30, a number that beat consensus estimates by 1.8% and sent BATS.L up 3.2% on the day. The real story was not the headline revenue but the internal composition shift. New Categories revenue jumped 18% at constant currency to GBP 1.93 billion, now representing 15.8% of group revenue, up from 13.1% a year ago.

BAT H1 2026 Performance Breakdown

The U.S. Vapor recovery is the headline most investors were waiting for. After two consecutive halves of negative growth, Vuse returned to double-digit expansion, driven by two factors: the Vuse Solo refillable system gaining traction in states with disposable bans, and the Allo brand partnership adding 4,200 new retail doors in Q2 alone. Circana data shows Vuse holds 34.2% U.S. e-cigarette market share, maintaining its position as the category leader.

Modern Oral was the standout performer across all segments. The Velo portfolio grew 65.9% to GBP 412 million, with the UK, Sweden, and Germany as the primary markets. BAT now holds 39.2% volume share in its top five oral nicotine markets, a 7.4 percentage point gain from H1 2025. The company invested GBP 280 million in its Krakow, Poland Velo production facility, which became operational in June 2026 and will serve as the primary supply hub for European markets.

“BAT’s H1 results confirm that the oral nicotine category has crossed from novelty to infrastructure. The 65.9% growth in Modern Oral is not a one-time spike; it reflects a structural consumer migration that will persist through 2028. The Krakow facility gives BAT the manufacturing scale to compete with PMI’s ZYN on cost per unit.”

— Barclays European Tobacco Research, August 2026

However, BAT faces a critical overhang: the UK disposable vape ban effective June 2026 compressed Vuse volumes in its largest single market by 8.3%. The TPD3 proposed flavor restrictions add further uncertainty, potentially impacting flavored cartridges that represent 42% of EU Vuse sales. Management stated it is developing a TPD3-compliant Vuse line for potential EU relaunch in 2027, focusing on tobacco-only and menthol flavors.

PMI’s VEEV inPRIME launch targets South Korea’s KRW 2.8 trillion e-cigarette market with a direct pod-system challenge.

PMI VEEV inPRIME Korea: The Closed-Pod Gauntlet

Philip Morris Korea announced the August 18 launch of VEEV inPRIME, a closed-pod e-cigarette system that represents PMI’s most aggressive push into the Korean market since IQOS. The device retails at KRW 29,000 (~$20.60), with VEEBI inPRIME pods priced at KRW 8,000 (~$5.68) for 2ml cartridges. Pre-sales began August 11 at IQOS flagship stores, with broader retail distribution starting August 26.

VEEV inPRIME Product Specs

The Korean e-cigarette market is valued at approximately KRW 2.8 trillion (~$2.0 billion) and growing at 12% annually, making it the third-largest closed-pod market in Asia after Japan and China. KT&G’s lil SOLID dominates with 42% market share, followed by RELX at 18% and Altria’s Myblu at 11%. PMI currently holds just 7% of the Korean e-cigarette market through its existing VEEV One platform, but the inPRIME launch signals a step-change in ambition.

Two strategic factors make this launch significant. First, the aggressive pricing undercuts both KT&G and RELX on device cost while maintaining pod-level margins that support sustained marketing investment. Second, PMI is leveraging its existing IQOS retail footprint of 2,800 stores across South Korea, providing immediate distribution depth that no competitor can match. The inPRIME launch will be supported by a KRW 45 billion ($32 million) marketing budget, the largest single-product campaign in PMI Korea’s history.

“The VEEV inPRIME launch is PMI declaring that it will no longer cede the closed-pod market to KT&G and RELX in Asia. The $32 million marketing budget tells you this is not an experiment; it is a full market-entry push. If PMI can achieve even 12% market share within 18 months, it will add roughly $240 million in annualized revenue from Korea alone.”

— Jefferies Asia Tobacco Coverage, August 2026

The FDA’s continued authorization of On! pouch products signals regulatory acceptance of oral nicotine as a reduced-risk category.

Altria On! FDA Wave: Volume Play Gains Regulatory Momentum

The FDA authorized four new On! nicotine pouch products on August 5, manufactured by Altria subsidiary Helix Innovations. The newly authorized flavors and strengths are Rich Berry 3mg, Rich Berry 6mg, Wintergreen 6mg, and Wintergreen 12mg. This brings the total number of authorized On! SKUs to 30, making On! the most diversified authorized pouch portfolio in the U.S. market after PMI’s ZYN.

The authorization is strategically significant for two reasons. First, it validates Altria’s regulatory strategy of pursuing incremental FDA clearances across flavor and strength combinations, building a broad authorized portfolio that creates shelf-space defensibility. Second, the Wintergreen 12mg strength targets the high-nicotine user segment that ZYN has not fully penetrated, giving Altria a differentiated positioning.

U.S. Nicotine Pouch Market Share (H1 2026)

Altria’s On! brand has been the fastest-growing pouch line in 2026, with H1 volume up 38.7% year-over-year. The company is expanding manufacturing capacity at its Richmond, Virginia facility, with a new production line expected to come online in Q4 2026, adding 200 million units of annual capacity. Altria has also begun rolling out On! Plus, a next-generation formulation with enhanced flavor delivery technology, in select test markets.

The FDA authorization wave is part of Altria’s broader strategy to build regulatory moats around its oral nicotine portfolio. The company now holds 30 authorized On! SKUs across five flavors and four strength levels, providing the retail shelf diversity needed to compete with ZYN’s dominant market position. Altria CEO Billy Gifford stated on the Q2 earnings call that On! is targeting 22% U.S. pouch market share by year-end 2026.

“Altria’s 30-SKU On! portfolio gives it more FDA-authorized pouch products than any competitor. In a market where retail shelf space is the binding constraint, SKU count translates directly to revenue. The Wintergreen 12mg authorization is particularly clever; it targets the high-nicotine segment where ZYN has the weakest coverage.”

— Morgan Stanley U.S. Tobacco Coverage, August 2026

Stock Performance: Three Divergent Narratives

The stock market is beginning to differentiate between the three companies’ strategic bets. As of August 11, the year-to-date performance reflects distinct investor assessments:

Valuation multiples reveal investor preference for PMI’s diversified smoke-free model over pure-play or legacy tobacco positions.

The valuation spread tells the story. PMI commands a 21.4x forward P/E premium, reflecting the market’s confidence in its multi-category smoke-free transition (IQOS + ZYN + VEEV). BAT trades at 11.2x, a value play with a 7.1% dividend yield that requires TPD3 resolution to unlock re-rating potential. Altria at 10.8x is the cheapest major tobacco name, but its 6% smoke-free revenue share and combustibles-heavy portfolio cap the multiple.

KT&G’s -4.2% YTD decline is directly attributable to PMI’s VEEV inPRIME entry. The Korean company’s 42% domestic market share faces its first credible multinational competitor in the closed-pod segment, and investors are pricing in the margin pressure. RELX remains the worst performer at -11.4% YTD, weighed down by STMA regulatory tightening and Southeast Asian ban headwinds.

Strategic Implications for the Supply Chain

The three companies’ divergent strategies are creating distinct supply chain demand patterns that manufacturers and component suppliers need to track:

• BAT’s U.S. Vapor Recovery: Vuse’s return to double-digit growth is driving refillable pod component orders. Suppliers of precision-engineered ceramic coils, PCTG pod shells, and mouthpiece assemblies are seeing order books extend 14-18 months. The 4,200 new retail doors added in Q2 require incremental inventory build of approximately 18 million pods for H2 2026 launch support.
• PMI’s Korea Closed-Pod Push: The VEEV inPRIME launch creates demand for 50-80 million VEEBI pods annually from Shenzhen-based pod manufacturers. PMI’s existing VEEV supply chain is primarily European (Poland-based), but the Korea launch will require Asian sourcing to maintain cost competitiveness against KT&G and RELX local production.
• Altria’s On! Volume Scale: The Richmond production expansion adds 200 million units of annual capacity, requiring new supply contracts for nicotine salt formulations, PET film pouches, and canister packaging. On! Plus formulation testing in select markets may create additional R&D demand for flavor encapsulation technology.

“The supply chain bifurcation is accelerating. Pod-system component suppliers serving BAT and PMI are entering a 24-month order visibility window, while disposable-focused OEMs in Shenzhen are seeing inquiry volumes drop 22% month-over-month. The winners in this transition are the component makers who pivoted early to refillable precision engineering.”

— Barclays Capital Markets, Tobacco Supply Chain Report, August 2026

Investor Outlook: Positioning for H2 2026

For investors and industry operators, the August 2026 landscape presents three distinct investment theses:

1. BAT (BATS.L) — Value + Recovery: At 11.2x forward P/E with a 7.1% dividend yield, BAT offers the most attractive risk-adjusted entry point in the nicotine sector. The U.S. Vapor recovery and Modern Oral growth provide earnings visibility, but TPD3 resolution is the catalyst needed for a re-rating toward 13-14x P/E. Target: 3,600p (11% upside from current levels) contingent on TPD3 clarity by Q4 2026.
2. PMI (PM) — Premium for Diversification: PMI’s 21.4x P/E premium reflects its status as the only large-cap nicotine company with three revenue-generating smoke-free platforms (IQOS, ZYN, VEEV). The Korea launch adds geographic diversification, but the premium requires continued execution. Risk: any ZYN capacity disruption or IQOS Japan market share loss would trigger multiple compression. Hold for existing investors; wait for pullback below $110 for new entries.
3. Altria (MO) — Dividend Income with Oral Nicotine Optionality: Altria’s 8.2% dividend yield makes it the income play in the nicotine sector. The On! portfolio expansion to 30 authorized SKUs and 18.4% market share provides a growth option that is not yet priced into the 10.8x P/E. The On! Plus rollout in H2 2026 could be a positive catalyst if early market data shows traction. Target: $65 (10% upside) by year-end 2026.
4. KT&G (033780.KS) — Watchlist Candidate: At 9.8x P/E, KT&G is statistically cheap, but PMI’s VEEV inPRIME launch creates a competitive overhang that will take 2-3 quarters to assess. Wait for Q4 2026 Korean market share data before establishing a position. If KT&G maintains above 35% share, the stock represents a contrarian value opportunity.